News

Ceres Nanosciences Establishes Five New Wastewater-Based Epidemiology Centers of Excellence Under NIH RADx Initiative

Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of five new wastewater-based epidemiology centers of excellence at the Houston Health Department, Morgan State University, the Nebraska Public Health Laboratory, the State Hygienic Laboratory at the University of Iowa, and the University of Missouri. The new centers add to the sixteen existing centers of excellence previously announced in April 2022, all of which have been established with support from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) initiative.

These 21 sites encompass testing labs located all across the country, including in Arizona, California, Connecticut, Illinois, Iowa, Georgia, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Missouri, Nebraska, New York, Texas, West Virginia, and Wisconsin.

“These sites have provided wastewater testing services for hundreds of locations and more than 100 million people across more than 50 states and territories in the United States,” said Ben Lepene, Chief Technology Officer at Ceres Nanosciences. “This is truly an amazing national public health infrastructure that Ceres and the NIH have stood up in such a short period of time.”

Each center of excellence received the materials and on-site training to implement an automated Nanotrap® particle protocol, which enables same-day delivery of wastewater testing results for over 100 samples per day. Extracted nucleic acids from this automated protocol are compatible with multiple nucleic acid detection methods, including reverse transcription-quantitative polymerase chain reaction (RT-qPCR), digital PCR (dPCR), droplet digital PCR (ddPCR), and genomic sequencing.

The sites are regularly sharing results with local and state public health authorities, the CDC National Wastewater Surveillance System (NWSS), and are presenting them on public-facing dashboards. In addition to reporting on the levels of COVID-19 detected in wastewater samples, many of these sites are monitoring COVID-19 variant groups and emerging pathogens like mpox, influenza, RSV, and enteric viruses such as norovirus.

 

Learn more here.

Recent News

10/07/2026

Kaléo Awarded $96.1 Million BARDA Contract to Advance 2-PAM Auto-Injector for U.S. Chemical Threat Preparedness

Kaléo, a global leader in drug-delivery device technology and auto-injector innovation, today announced it has been awarded a Project BioShield contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to support the late-stage development, …

10/05/2026

Virginia Ranked No. 1 in Nation for Workforce Training Program by Area Development

Governor Abigail Spanberger today celebrated that Virginia has been ranked No. 1 in the nation for its workforce training program in Area Development’s 2026 Top States for Doing Business report — reinforcing the Commonwealth’s position as a top state for talent and a national leader in preparing Virginians for high-quality jobs. “Virginia is building the …

09/30/2026

Activation Capital Recognizes President Michael Rao’s 17 Years of Leadership as Authority Board Chair, Names Paul Nolde as New Chair

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced the election of Paul Nolde as chair of the Authority Board, succeeding Virginia Commonwealth University President Michael Rao, Ph.D., who has served as chair since 2009. Rao will remain an active member of the board, continuing his longstanding support of Activation …